GS 9191

Drug Profile

GS 9191

Alternative Names: GS-9191

Latest Information Update: 15 Dec 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Human papillomavirus infections

Most Recent Events

  • 02 Dec 2011 Medicis Pharmaceutical Corporation acquires pharmaceuticals assets of Graceway Pharmaceuticals
  • 02 Dec 2011 No development reported - Phase-I for Human papillomavirus infections in USA (Topical)
  • 07 Nov 2009 GS 9191 is in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top